First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China

First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China

Abstract. Background:. Nucleos(t)ide analog (NA) in combination with peginterferon (PegIFN) therapy in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) shows better effectiveness than NA monotherapy in hepatitis B surface antigen loss, termed “functional cure,” based on...

Full description

Bibliographic Details
Main Authors: Xue-Ru Yin, Zhi-Hong Liu, Jing Liu, Yuan-Yuan Liu, Li Xie, Li-Bo Tao, Ji-Dong Jia, Fu-Qiang Cui, Gui-Hua Zhuang, Jin-Lin Hou, Li-Min Chen
Format: Article
Language:English
Published: Wolters Kluwer 2019-10-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000000445

Internet

http://journals.lww.com/10.1097/CM9.0000000000000445

Similar Items